Recent Analysts’ Ratings Changes for Celcuity (CELC)

Celcuity (NASDAQ: CELC) has recently received a number of price target changes and ratings updates:

• 11/9/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup.
• 11/9/2026 – Celcuity had its price target lowered by HC Wainwright from $155.00 to $150.00. They now have a “buy” rating on the stock.
• 11/6/2026 – Celcuity is now covered by Guggenheim. They set a “buy” rating and a $169.00 price target on the stock.
• 10/28/2026 – Celcuity was downgraded by Royal Bank Of Canada to “neutral”.
• 10/22/2026 – Celcuity is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $140.00 price target on the stock.
• 10/21/2026 – Celcuity had its “buy” rating reaffirmed by TD Cowen. They now have a $145.00 price target on the stock.
• 10/19/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup.
• 10/13/2026 – Celcuity was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/30/2026 – Celcuity had its price target lowered by Needham & Company LLC from $140.00 to $134.00. They now have a “buy” rating on the stock.
• 9/17/2026 – Celcuity is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $157.00 price target on the stock.

Celcuity Stock Performance

NASDAQ:CELC opened at $66.79 on Monday. The firm has a market capitalization of $3.27 billion, a PE ratio of -14.18 and a beta of 0.16. The business’s fifty day moving average price is $75.11 and its 200 day moving average price is $99.38. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. Celcuity, Inc. has a 12 month low of $53.54 and a 12 month high of $151.02.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.30. On average, sell-side analysts anticipate that Celcuity, Inc. will post -4.98 earnings per share for the current fiscal year.

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways.

Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity conducts clinical development in the United States and internationally.